Introduction
Evidence acquisition
Study | Type | Setting | Intervention | Inclusion | Imaging | N (study arm/control arm) | Median FU | Evaluated clinical outcomes |
---|---|---|---|---|---|---|---|---|
STOMP (2018) [3] | RCT | 100% mHSPC | SBRT or metastasectomy vs. observation | 1–3 extracranial metastases, asymptomatic biochemical recurrence following curative treatment (no ADT, no local relapse, serum testosterone levels >50 ng/mL); ECOG ≤ 1 | Choline PET | 31/31 | 36 | ADT-free survival, PSA progression, local progression |
ORIOLE (2020) [2] | RCT | 100% mHSPC | SBRT vs. observation | 1–3 asymptomatic metastases after primary curative treatment, and no ADT within 6 months of enrolment | Conventional imaging | 36/18 | 19 | Progression-free survival, biochemical progression-free survival, distant metastases-free survival |
Pan (2022) [14] | nCT | Non-metastatic PC patients based on conventional imaging who experienced early PSA (prostate-specific antigen) progression on ADT | SBRT vs. ADT in control group | 1–5 bone or lymph node metastases and early PSA progression on ADT following curative treatment; ECOG ≤ 1, life expectancy > 12 months | PSMA-PET | 29/18 | 21 | Metastasis-free survival |
POPSTAR (2018) [9] | SA | 67% mHSPC, 33% mCRPC | SRS | 1–3 bone or lymph node metastases following curative treatment; ECOG ≤ 2 | NaF-PET | 33 | 24 | Local progression-free survival, distant progression-free survival, ADT-free survival, PSA response |
Kneebone (2018) [10] | SA | 100% mHSPC | SRS or SBRT | 1–3 lymph node or bone metastases following biochemical recurrence after primary curative treatment | PSMA-PET | 57 | 16 | Progression-free survival, biochemical progression-free survival, distant metastases-free survival |
Glicksman (2022) [11] | SA | 100% mHSPC | SBRT or metastasectomy | 1–6 metastases following biochemical recurrence after RP and postoperative RT +/− ADT | PSMA-PET | 74 | 24 | Biochemical response, PSA progression-free survival, ADT-free survival, salvage treatment-free survival, CRPC-free survival |
SA | 100% mHSPC | SBRT or conventional RT | 1–5 bone or lymph node metastases following local curative therapy and PSA ≤ 10 ng/mL; Life expectancy ≥ 5 years | PSMA-PET | 63 | 37 | PSA progression-free time, time to start systemic therapy, progression-free survival, overall survival. local progression-free time, time to the first tumor-related clinical event |
Study | Setting | Intervention | Planned cohort size | Primary endpoint |
---|---|---|---|---|
NCT05352178 (SPARKLE) | Oligorecurrent disease | MDT alone vs. MDT + 1 month of ADT vs. MDT + 6 months of ADT | 873 | Poly-metastatic-free survival (PMFS) |
NCT04302454 (ADOPT) | Oligometastatic disease | MDT alone vs. MDT + ADT | 280 | Metastases progression-free survival (MPFS) |
NCT04787744 (VA STARPORT) | Oligorecurrent disease | SOC systemic therapy + MDT vs. SOC systemic therapy | 464 | Radiographic progression-free survival (rPFS) |
NCT04423211 | Oligorecurrent disease | MDT + SOC treatment vs. SOC treatment alone | 804 | Progression-free survival (PFS) |
NCT04983095 (METRO) | Oligometastatic disease | MDT + SOC treatment vs. SOC treatment alone | 114 | Failure-free survival |
NCT04115007 (PRESTO) | Oligometastatic disease | MDT + SOC treatment vs. SOC treatment alone | 350 | Castration-resistant prostate cancer-free survival |